Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.

Hematology/oncology clinics of North America - 1 Oct 2025

Vom Stein Alexander F, Frenzel Lukas P

Abstract excerpt

Chronic lymphocytic leukemia (CLL) treatment has evolved with the introduction of venetoclax, a selective BCL-2 inhibitor capable of inducing apoptosis in CLL cells. However, resistance has emerged as a significant clinical obstacle. Here, we delineate the multifactorial basis of venetoclax resistance in CLL by exploring genetic mutations, epigenetic alterations, microenvironmental protection, metabolic rewiring,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Share to Tumor Microenvironment

Source

Identifiers

PMID: 40695714
DOI: 10.1016/j.hoc.2025.06.001

Genes

BCL2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.PMID 40695714Read ↗

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistanceSemantic proximity Read ↗

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesSemantic proximity Read ↗

When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel AgentsSemantic proximity Read ↗

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignanciesSemantic proximity Read ↗

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaSemantic proximity Read ↗

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.Semantic proximity Read ↗

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignanciesSemantic proximity Read ↗

Mechanisms of venetoclax resistance and solutionsSemantic proximity Read ↗

Venetoclax resistance: mechanistic insights and future strategiesSemantic proximity Read ↗

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapySemantic proximity Read ↗

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.